Concord Drugs Faces Financial Challenges Amid Shifting Market Indicators and Low Profitability
Concord Drugs, a microcap in the Pharmaceuticals & Biotechnology sector, has recently experienced an evaluation adjustment reflecting changes in its trends. The company reported a net sales figure of Rs 10.39 crore for the quarter ending March 2025, alongside a challenging performance characterized by a -17.70% return over the past year.
Concord Drugs, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects changes in its underlying trends. The stock's technical indicators have shifted, with the technical trend moving from bearish to mildly bearish. This adjustment is influenced by various metrics, including the MACD, which shows a mildly bullish signal on a weekly basis while remaining bearish on a monthly basis. The company's performance over the past year has been characterized by a return of -17.70%, which is notably below the BSE 500 index. Additionally, the company reported a net sales figure of Rs 10.39 crore for the quarter ending March 2025, marking a low point in its financial performance. Over the last five years, Concord Drugs has experienced a -4.49% CAGR growth in operating profits, indicating challenges in long-term fundamental strength.
Despite these hurdles, the stock is trading at a discount compared to its peers' average historical valuations, suggesting a complex market position. The company's return on equity stands at 1.83%, reflecting low profitability per unit of shareholders' funds.
For those interested in further insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
